| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CORT | Common Stock | Tax liability | -$8.19K | -232 | -0.27% | $35.30 | 84.2K | Sep 3, 2024 | Direct | F1, F2, F3 |
| transaction | CORT | Common Stock | Award | $15.7K | +458 | +0.54% | $34.26 | 84.6K | Sep 3, 2024 | Direct | F3, F4, F5 |
| transaction | CORT | Common Stock | Award | $0 | +458 | +0.54% | $0.00 | 85.1K | Sep 3, 2024 | Direct | F3, F6 |
| holding | CORT | Common Stock | 10K | Sep 3, 2024 | See Footnote | F7 | |||||
| holding | CORT | Common Stock | 10K | Sep 3, 2024 | See Footnote | F8 |
| Id | Content |
|---|---|
| F1 | These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. |
| F2 | The closing price on August 30, 2024 was used to calculate the withholding obligation. |
| F3 | Includes 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| F4 | The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 3, 2024. |
| F5 | In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. |
| F6 | Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. |
| F7 | Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
| F8 | Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. |
President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.